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Abstract
Background: Glioblastoma multiformae (GBM) is the most aggressive type of malignant brain tumor with complex
molecular profile. Overexpression of Na+/H+ Exchanger isoform 9 (NHE9) promotes tumor progression and
correlates positively with insensitivity to radiochemotherapy and poor prognosis. However, molecular mechanisms
responsible for increase in NHE9 levels beyond a critical threshold have not been identified.
Methods: Bioinformatics analysis, luciferase reporter assays, real-time PCR and western blotting were conducted to
examine the expression profiles and identify microRNAs (miRNA) that target NHE9. Cell proliferation and migration
assays were conducted in U87 glioblastoma cells to determine the consequence of miRNA mediated targeting of
NHE9. Endosomal pH measurements, immunofluorescence microscopy and surface biotinylation experiments were
conducted to characterize the mechanistic basis of regulation.
Results: We show that microRNA 135a (miR-135a) targets NHE9 to downregulate its expression in U87 cells. MiR-
135a levels are significantly lower in glioblastoma cells compared to normal brain tissue. Downregulation of NHE9
expression by miR-135a affects proliferative and migratory capacity of U87 cells. Selectively increasing NHE9
expression in these cells restored their ability to proliferate and migrate. We demonstrate that miR-135a takes a
two-pronged approach affecting epidermal growth factor receptors (EGFRs) to suppress tumor cell growth and
migration. EGFR activity is a potent stimulator of oncogenic signaling. While miR-135a targets EGFR transcripts to
decrease the total number of receptors made, by targeting NHE9 it routes the few EGFRs made away from the
plasma membrane to dampen oncogenic signaling. NHE9 is localized to sorting endosomes in glioblastoma cells
where it alkalinizes the endosome lumen by leaking protons. Downregulation of NHE9 expression by miR-135a
acidifies sorting endosomes limiting EGFR trafficking to the glioblastoma cell membrane.
Conclusions: We propose downregulation of miR-135a as a potential mechanism underlying the high NHE9
expression observed in subset of glioblastomas. Future studies should explore miR-135a as a potential therapeutic
for glioblastomas with NHE9 overexpression.
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Background
Glioblastoma multiformae (GBM) are the most lethal
primary brain tumors [1, 2]. Characterized by rapidly in-
vasive growth pattern and high angiogenesis, complete
surgical resection of GBM is extremely difficult [3]. Even
with surgery and radiochemotherapy the median survival
for patients is 12–15 months [3]. Accumulating evidence
suggests molecular heterogeneity is a key hurdle in im-
proving clinical outcomes [4–6]. Effective treatment
strategies should therefore be tailored to a patient’s
unique tumor genetic makeup [4, 5]. Identifying specific
genetic subsets of tumors and using these as therapeutic
targets is now a major focus of glioma research [7]. In
GBM, increase in Na+/H+ Exchanger NHE9 protein
levels has recently been identified as a potent driver of
tumor progression and is associated with decreased
patient survival [7].
SLC9A9 gene encoding NHE9 is one of the top 12% of
the genes overexpressed in GBM [7]. Following neo-
adjuvant chemotherapy and tumor resection, GBM pa-
tients overexpressing NHE9 remained disease free for
~11 months with median survival of only 16 months com-
pared to patients with unaltered expression of NHE9 who
remained disease free for ~34 months with median sur-
vival of ~59 months [7]. Moreover, overexpression of
NHE9 in GBM correlates positively with radiochemother-
apy insensitivity [7, 8]. In glia, NHE9 is localized to sorting
endosomes [9] where it regulates endosomal pH by trans-
porting protons out in exchange for sodium or potassium
ions [10–13]. Overexpression of NHE9 alkalinizes the
sorting endosomes and thereby affects sorting of epider-
mal growth factor receptors (EGFRs) [7]. EGFR signaling
regulates multiple cellular functions including cell growth
and division [14]. Dysregulated EGFR activity is character-
istic of GBM oncogenic signature [15]. Endocytosis of
EGFRs removes the receptors from the membrane follow-
ing which they are routed to the lysosome, thereby ter-
minating the signaling [16]. Increased NHE9 activity
redirects EGFR to the plasma membrane resulting in acti-
vation of downstream oncogenic signaling pathways [7].
The mechanisms underlying overexpression of NHE9 in
GBM have not been studied. In wake of the emerging
roles in cancer, we focused on the microRNA (miRNA)
mediated regulation of NHE9 and EGFR-dependent onco-
genic signaling.
MicroRNAs are 19–24 nucleotide single-stranded non-
coding RNAs that can regulate gene expression at both
post-transcriptional and translational levels [17]. MiR-
NAs interact specifically with 3’untranslated regions
(UTRs) of messenger RNA (mRNA) to decrease the sta-
bility of mRNAs leading to reduced expression of pro-
tein [17]. Deregulation of miRNA expression has been
observed in many cancers including glioma [18–20]. In
comparison to normal brain, deregulation of more than
290 miRNAs has been reported in GBM [18]. It is well
established in preclinical models that restoring miRNA
levels can inhibit tumor growth, consistent with func-
tional role for miRNAs as tumor suppressors [21]. How-
ever, each miRNA is capable of targeting multiple genes
[22–24]. Manipulation of miRNA levels can have impli-
cations on biological processes globally. Therefore, miR-
NAs that are enriched in or specific to tissue of interest
are potentially promising candidates for therapy. Several
therapeutic miRNA mimics are in preclinical and clinical
stages of development [21, 25, 26]. MiRNAs are stable in
tissue and body fluids and could also serve as non -inva-
sive biomarkers of cancer [27]. Identifying miRNAs that
target NHE9 transcript in glia thus hold great promise
for a subset of GBM patients.
In this study, we identified miR-135a as a regulator of
NHE9 protein expression. MiR-135a, a glial cell enriched
miRNA, is known to be downregulated in glioma [28].
Here, we examined the regulation of NHE9 by miR-135a
in a well-characterized GBM cell model. We demon-
strate that miR-135a downregulates EGFR and NHE9
protein expression to attenuate membrane turnover of
EGFRs to impair GBM cell growth and ability to mi-
grate. We propose a potential therapeutic role for miR-
135a in GBM with NHE9 overexpression.
Methods
Glioma cell lines, plasmids and miRNA mimics
U87 cells were obtained from Dr. Alfredo Quiñones-
Hinojosa’s laboratory (Johns Hopkins University, cur-
rently at Mayo Clinic). U251n cells were obtained from
Dr. Feng Jiang’s laboratory (Henry Ford Hospital). U87
and U251 cells were maintained in DMEM media (Invi-
trogen) supplemented with 10% fetal bovine serum
(Sigma), and 5% Antibiotic-Antimycotic (10,000 U/ml
penicillin, 10,000 mg/ml streptomycin, Gibco). Cells
were maintained in a 5% CO2 incubator at 37 °C. The
growth medium was completely exchanged with fresh
medium twice a week. Micro-RNA mimics, hsa-miR-
135a-5p, hsa-153-3p and hsa-124-3p as well as the
scrambled control (miRIDIAN microRNA Mimic Nega-
tive Control #1) were purchased from Dharmacon.
Transfection effeciencies were optimized using miRI-
DIAN microRNA Mimic Transfection Control with
Dy547 (Dharmacon). Full-length mNHE9-EGFP and
mNHE9-mcherry were cloned into FuGW lentiviral vec-
tor as previously described [9]. Empty vector (FuGW)
was used for control transductions. Viral Core Facility of
the University of Michigan executed lentiviral packaging
of the virus.
Computational analysis
MiRNAs targeting NHE9 transcript were predicted
through the algorithms TargetScan Human 5.2 (http://
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www.targetscan.org) [29]. We obtained miRNA abun-
dance in various human tissues from the human miRNA
tissue atlas (https://ccb-web.cs.uni-saarland.de/tissueatlas/)
[30]. SLC9A9 transcript abundance in various tissues
was obtained from published RNA-seq analysis of tis-
sue samples from 95 human individuals (https://
www.ncbi.nlm.nih.gov/gene/285195/?report=expression) [31].
Comparative analysis for miR-135a and NHE9 mRNA
expression in various tissues is presented as percent
relative to tissue of highest expression.
Luciferase reporter assay
One thousand four hundred ninety three base pairs of
SLC9A9 (NM_173653) 3’UTR cloned in pMIR target vector,
with firefly luciferase as reporter, was purchased from Ori-
gene (SC214935). Luciferase assays were carried out in HEK
293 and U87 cells. Cells were co-transfected with mimics
hsa-miR-135a-5p, hsa-153-3p and hsa-124-3p or scrambled
control mimic in 24-well plates. The cells were then har-
vested and lysed for luciferase assay 48 h after transfection.
Luciferase assays were performed using a luciferase assay kit
(Promega) according to the manufacturer’s instructions.
RNA isolation and qPCR
Total RNA from human brain tissue was obtained from
Agilent Technologies. MiRNA was extracted from U87
and U251n cells using miRNeasy kit (Qiagen) following
manufacturer’s instructions. cDNA was synthesized
using miScript II RT kit (Qiagen) according to the man-
ufacturer’s instructions. Quantitative real-time PCR ana-
lysis experiments were set up using miScript SYBR
Green PCR Kit (Qiagen) according to manufacturer’s in-
structions on CFX connect real time system (Bio-Rad
Laboratories). MiScript Primer Assay probes used were:
MS00008624 (has-miR-135a-5p) and MS00033705
(Hs_SNORD61_11). mRNA was isolated from U87 cells
using the RNeasy Mini kit (Qiagen) following manufac-
turer’s instructions as previously described. Taqman
gene expression assay probes used were: Hs02758991_g1
and Mm99999915_g1 (GAPDH), Hs00543518_m1 and
Mm00626012_m (NHE9). Cycle threshold (Ct) values
were first normalized to endogenous controls. Fold
change was calculated as 2−ΔΔCt, where ΔΔCt is the nor-
malized cycle threshold value relative to control. At least
three technical replicates of three biological replicates
were run to account for variance in assays.
Indirect immunofluorescence
U87 cells on coverslips were washed twice with phos-
phate buffered saline (PBS). The cells were then fixed
for 30 min at room temperature with solution con-
taining 4% PFA and 4% sucrose in PBS, following
previously published protocol [32]. For EGFR sorting
experiments, cells were starved and then stimulated
with 20 ng mL−1 EGF for 1 h at 37 °C before fixing.
Fixing solution was removed by washing with PBS.
Next, the cells were incubated for a half-hour in
block solution (1%BSA, 0.3 M glycine, and 0.1%
tween 20). For co-localization experiments with
NHE9-GFP, Rab 5 antibody (Cell Signaling Technol-
ogy) was diluted 1:100 in block solution without
tween 20 and incubated overnight at 4˙C. Following
PBS washes, Alexa Fluor conjugated secondary anti-
body (Invitrogen, USA) was used at 1:1000 dilutions
for 30 min. Cells were mounted onto slides using
Prolong gold antifade reagent (Invitrogen) and were
imaged using Lumascope-620 microscope (Etaluma).
qPCR analysis
mRNA was isolated using the RNeasy Mini kit (Qiagen)
following manufacturer’s instructions with an additional
step to remove DNA using DNase I (Ambion, Thermo
fisher Scientific). cDNA was synthesized using the High-
Capacity RNA-to-cDNA Kit (Applied Biosystems)
following manufacturer’s instructions. Quantitative real-
time PCR analysis experiments were set up using Taqman
fast universal PCR Master Mix (Applied Biosystems) ac-
cording to manufacturer’s instructions on CFX connect
real time system (Bio-Rad Laboratories). Taqman gene ex-
pression assay probes used were: Hs02758991_g1 and
Mm99999915_g1 (GAPDH), Hs00543518_m1 and
Mm00626012_m (NHE9), 1Hs00951083_m1 (TfR),
Hs03003631_g1 (18 s rRNA). Cycle threshold (Ct) values
were first normalized to endogenous controls. Fold change
was calculated as 2−ΔΔCt, where ΔΔCt is the normalized
cycle threshold value relative to control. Three technical
replicates of three biological replicates were run to ac-
count for variance in assays.
Surface Biotinylation and western blotting
U87 cells were EGF starved for 2 h. Following which,
20 ng mL−1 EGF was added to the media for 30 min and
surface proteins were labeled with biotin as previously
described [9, 32]. Briefly, cells were washed with ice-cold
PBS at least 3 times and incubated with Sulfo-NHS-LC-
biotin at 1 m/ml in PBS for 20 min at 4 °C. Excess NHS
groups were quenched using glycine (100 mM). Cells
were lysed with Mammalian Protein Extraction Reagent
(M-PER, Thermo Fisher Scientific) that included prote-
ase inhibitor cocktail (Halt Protease Inhibitor Cocktail,
Thermo Fisher Scientific) and separated by SDS-
polyacrylamide gel electrophoresis as previously de-
scribed. NHE9 antibody used for western blotting was
purchased from ProteinTech (catalog #13718–1-AP)
and EGFR antibody was purchased from Millipore
(catalog# 06–847). Both these antibodies were used at
1:100 dilutions. Loading control used was tubulin
(Sigma T 9026, 1:1000).
Gomez Zubieta et al. Cell Communication and Signaling  (2017) 15:55 Page 3 of 12
Cell proliferation assay
Cell proliferation was quantified using MTS assay (Cellti-
ter 96 Aqueous One Solution Cell Proliferation Assay,
Promega). This is a calorimetric assay, which works on
the principle of Owens reagent being converted into a col-
ored formazan product by viable cells. Briefly, 1 × 104 cells
were seeded, in triplicate, into a 96-well plate. U87 cells
plated in 96 well plates were transfected with 100 nm of
miR-135a mimic or the control using Lipofectamine LTX
(Thermo Fisher Scientific). For NHE9 overexpression,
U87 cells were transduced with lentiviral vector express-
ing NHE9-GFP as described previously [32]. MiRNA
mimics were transfected in these cells 24 h after transduc-
tion. At each time point, 20 μl of Celltiter 96 Aqueous
One Solution reagent was added to each well and incu-
bated for 1 h at 37 °C. The absorbance was measured at
490 nM using a microplate reader (BioRad, iMark) and
normalized to the samples absorbance on day 1.
Cell migration assay
Oris Migration Assay (Platypus Technologies) was used to
monitor U87 cell migration. Briefly, U87 cells were seeded
in a 96 well plate (3.75 × 105 cells per well) with a physical
barrier (Silicone stopper) to create a central cell-free de-
tection zone in the center of each well. 48 h later cells
were then transfected with 100 nM miR-135a or control
mimic using Lipofectamine LTX (Thermo Fisher Scien-
tific). After 24-h, the stopper was removed and cells were
incubated with live cell nuclear counterstain NucBlue
(Thermo Fisher Scientific) for 20 min before monitoring
the migration process. Fluorescence images were taken
with Lumascope 620 (Etaluma) at various time points as
indicated. For NHE9 overexpression, U87 cells were trans-
duced with FUGW vector expressing NHE9-GFP as de-
scribed previously. miRNA mimics were transfected in
these cells 24 h after transduction.
Endosomal pH measurement
U87 cells plated in fluorodishes (World Precision Instru-
ments, FL, U.S.A.) were transfected with 100 nM miR-
135a or control mimic. 48 h after transfection the fluor-
odishes were placed on ice for 10 min and then rinsed
with cold imaging buffer (Live Cell Imaging Solution
(Thermo Fisher Scientific) with 20 mM Glucose and 1%
BSA) to remove residual transferrin. Cells were then incu-
bated with 50 μg/ml fluorescein conjugated transferrin
(Tfn-FITC, Thermo Fisher Scientific) in imaging buffer for
10 min. The cells were then rinsed with LCIS and fluores-
cence images were acquired (excitation 494 nm and emis-
sion 518 nm) with Lumascope 620 (Etaluma). Internal
a b
c d
Fig. 1 SLC9A9 transcript is a target of miR-135a-5p and miR-124-3p. a Seed sequences of miR-135a-5p, miR-124-3p and miR-153-3p along with
their predicted binding sites in SLC9A9 3’-UTR are shown. The highlighted regions represent the binding sites as predicted by TargetScan. b MiR-
135a-5p and miR-124-3p target the predicted binding sites within the transcript of SLC9A9 3’-UTR, decreasing luciferase activity in HEK293 cells
transfected with a luciferase reporter. Relative luciferase activity normalized to protein concentration is plotted. c Luciferase activity as described
in (b) is shown for U87 cells (d) Luciferase activity as described in (b) is shown for U251n cells. Error bars represent standard deviation (SD) determined
from at least three biological replicates; *p< 0.05. Statistical analysis was done using student’s t-test
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fluorescence was quantified using ImageJ [33] software,
and average fluorescence intensity was recorded. To
normalize for total transferrin uptake, pH insensitive
50μg/ml Alexa Fluor 568-conjugated transferrin (Tfn-568)
was loaded as described above in both control and mir-
135a transfected cells. Endosomal pH was determined
from a standard curve that was generated using pH cali-
bration buffer kit (Thermo Fisher Scientific). Briefly, cells
were incubated with 50 μg/ml fluorescein conjugated
transferrin for 10 min as described above and rinsed with
imaging buffer. The cells were then loaded with 10 μM
Cell Loading Solution (Thermo Fisher Scientific) that in-
cluded Valinomycin and Nigericin (10 μM each) and incu-
bated with calibration buffers of varying pH for 5 min at
37˙C, before fluorescence imaging.
Results
MiR-135a targets NHE9 and downregulates its expression
The most important feature for target recognition by
microRNAs (miRNAs) is a 6–8 neucleotide long se-
quence on the miRNA known as the seed sequence [34].
Seed sequences in miRNAs are known to interact with
target gene at multiple sites, both canonical and non-
canonical [35]. However, it has been shown that plural-
ities of miRNA-mRNA interactions that result in transla-
tional repression occur via canonical and conserved sites
[36]. As a first step to identify miRNAs that target
NHE9 we used an online miRNA target prediction pro-
gram TargetScan [29]. This program considers mRNA
binding site type and conservation among other features
to predict targets. TargetScan predicted miR-135a-5p,
153-3p and 124-3p as the most promising candidates.
These three miRNAs are broadly conserved among ver-
tebrates and have either a seven (miR-124-3p, 153-3p)
or eight (miR-135a-5p) nucleotide complementarity be-
tween miRNA seed region and the 3’UTR of NHE9 tran-
script (Fig. 1A). Though length of seed region alone
does not influence mRNA repression, prediction specifi-
city increases with seed length [37].
Next, we sought to experimentally validate interactions
of the three miRNAs with the 3’UTR of NHE9. For this,




Fig. 2 miR-135a-5p downregulates NHE9 protein expression. a Raw expression values of miR-135a, miR-124 and miR-153 were obtained from human
miRNA tissue atlas. MiRNA abundance in brain from tissue biopsies of two normal (i.e. cancer free) individuals was conducted using SurePrint 8 × 60 K
Human V19 and V21 miRNA microarray analysis as previously described [30]. b Comparative analysis of NHE9 mRNA and miR-135a expression profiles
across various tissues. NHE9 mRNA expression profile was obtained from RNA-seq analysis performed of human tissue samples from 95 normal (i.e.
cancer free) individuals as described previously [31]. MiRNA expression profile was obtained from human miRNA tissue atlas [30]. Normalization
was done as a percentage relative to tissue with highest expression. c Mir-135a expression levels in U87 and U251n cell lines relative to
normal human brain tissue. d qPCR analysis of miR-135a from U87 cells transfected with miR-135a mimic relative to control U87 cells. e
Immunoblots of U87 cell lysates transfected with miR-135a or scrambled control mimic were probed using anti-NHE9 and anti-tubulin
antibodies. f NHE9 protein expression levels determined by western blotting. Graphs represent average band intensity from densitometric
scans of immunoblots from three biological replicates. Error bars represent standard deviation (SD), *p < 0.05 and **p < 0.01. Statistical analysis
was done using student’s t-test
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connected at the downstream of a luciferase reporter
gene was co-transfected with miR-124, 135a, 153 mimics
or scrambled miRNA control in HEK293T cells. As
shown in Fig. 1B, miR-135a and miR-124 suppressed lu-
ciferase activity by ~ 70% and 40% respectively relative
to the scrambled control. Though we did see a ~25% re-
duction in luciferase activity with miR-153, under our
test conditions, the variation failed to achieve statistical
significance. A similar trend was observed when the
assay was repeated in U87 (Fig. 1C) and U251n glioblast-
oma cells (Fig. 1D). These results indicate that NHE9 is
a direct target of miR-135a and miR-124. MiRNA abun-
dance data of normal adult human brain obtained from
the miRNA tissue atlas indicates that miR-124 levels are
~125 and ~60 fold higher than miR-135a and miR-153
respectively (Fig. 2A) [30]. Interestingly, miR-135a is
enriched specifically in glial cells and is dramatically
downregulated in gliomas [28]. Previous studies in pros-
tate cancer cells also suggest a role for miR-135a in
downregulation of epidermal growth factor mediated
oncogenic signaling [38]. Therefore, we decided to focus
on miR-135a in this study. Analysis of published expres-
sion profiles of miRNA-135a and NHE9 mRNA from
various human tissues, as shown in Fig. 2B, revealed a
strong negative correlation consistent with mRNA deg-
radation mechanism involved in miR-135a–NHE9
interactions.
To investigate the role of miR-135a in glioblastoma
progression driven by NHE9, we first compared the ex-
pression levels of miR-135a in glioblstoma cell lines
(U87 and U251n) with total RNA from normal human
brain (frontal cortex). MiR-135a expression levels were
significantly lower in tumor cell lines compared to total
RNA from normal brain tissues (Fig. 2C). Expression of
miR-135a in U87 and U251 glioblastoma cell lines were
4.5% and 33% of normal brain tissue, respectively. This
data supports the idea of a tumor suppressor role for
miR-135a in glioblastoma. In the context of NHE9 pro-
tein expression driving oncogenic signaling in glioma,
we sought to test whether miR-135a downregulates
NHE9 protein levels in its role as a tumor suppressor.




Fig. 3 Downregulation of NHE9 expression via miR-135a affects U87 cell proliferation and migration. a Proliferation of U87 cells transfected with
miR-Scr or miR-135a were determined by MTS assay. Absorbance at 490 nm for each sample was normalized to the samples absorbance on day
1. b Loss of proliferative ability in miR-135a transfected U87 glioma cells is reversed by ectopic expression of NHE9-GFP. Proliferation determination
and normalization were done as described in (a). c Representative images of U87 cell migration assay taken at 0.5,16 and 26 h. Migration of U87 cells
into cell free zones (red dashed-circles) was detected using live cell nuclear counterstain NucBlue (white dots). Loss of migration capacity in miR-135a
transfected U87 glioma cells is reversed by ectopic expression of NHE9-GFP. Scale bar (yellow line) is 250 μm. (d and e) Graphs represent normalized
fluorescence intensity from NucBlue staining of live cells migrating into the cell free zones at various time points as indicated. Fluorescence intensity of
each sample was normalized to the samples fluorescence at 0.5 h. Error bars represent standard deviation (SD); **p < 0.01. Statistical analysis was done
using student’s t-test. Graph represents an average of at least three biological replicates
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increased miR-135a by 20 -fold in U87 cells (Fig. 2D).
Western blotting at 72 h after transfection with miR-
135a or scrambled control indicated NHE9 protein levels
were reduced by ~3.2 fold when transfected with miR-
135a compared to miRNA control in U87 cells (Fig. 2E
and F). These data clearly indicate that miR-135a targets
NHE9 to downregulate its expression.
MiR-135a inhibits glioblastoma cell proliferation and
migration by modulating NHE9 levels
MiR-135a has been reported to suppress the proliferation
of glioma cells [28]. Consistent with previous observa-
tions, evaluation of proliferation capacity by MTS assay
demonstrated that transfection of miR-135a reduced pro-
liferation of U87 cells by ~34% relative to control in 48 h
and ~40% in 96 h, after transfection (Fig. 3A). However,
the proliferative ability was regained by co-expression with
NHE9-GFP (Fig. 3B). This indicates NHE9 plays a role in
miR-135a mediated inhibition of glioblastoma cell growth.
NHE9 expression in U87 cells significantly increases mi-
gratory potential of U87 cells (Additional file 1: Figure S1).
MiR-135a inhibited migration of U87 glioblastoma cells
by ~50% relative to the control group, in 26 h (Fig. 3C left
and middle panels and 3D). Similar to cell proliferation,
ability to migrate was restored in cells when NHE9
protein levels were increased (Fig. 3C middle and right
panels and 3E). Together, these data indicate that miR-
135a regulates proliferation and migration in U87 glio-
blastoma cells via NHE9.
Downregulation of NHE9 expression via miR-135a alters
pH of sorting endosomes to affect EGFR trafficking in
glioblastoma cells
To determine the mechanistic basis of miR-135a di-
rected regulation, we confirmed the subcellular
localization of NHE9 in U87 cells. NHE9-GFP coloca-
lized with Rab5, a marker for sorting endosomes (Man-
ders’ coefficient, 0.51 ± 0.05 S.D., n = 50 cells) (Fig. 4A).
Previously, NHE9 has been shown to leak protons out of
the endosomes in glial cells. Therefore, we expected a
decrease in NHE9 protein expression by miR-135a to re-
sult in more acidic endosomes. To this end, we mea-
sured luminal pH of the sorting endosomes (pHe) using
pH-sensitive fluorescence of FITC-tagged transferrin.
There was no significant effect of miR-135a transfection
on recruitment of transferrin to the sorting endosomes
(Additional file 1: Figure S2). pHe was calibrated using
buffers of known pH (Fig. 4B). In U87 cells, as expected
pHe changed from 5.95 ± 0.12, to 5.63 ± 0.14 upon trans-
fection with mir-135a mimic (Fig. 4C).
a b
c
Fig. 4 miR135a acidifies sorting endosomes by downregulating NHE9. a NHE9-GFP colocalizes with Rab5 in sorting endosomes of U87 cells
as determined by immunofluorescence microscopy. Top panel: NHE9-GFP (green) Middle panel: sorting endosome marker, Rab5 (red) and
Bottom panel: Merge. Colocalization is indicated by yellow in the merge. Scale bar is 10 μm. Quantification of NHE9-GFP localization with
Rab5 in U87 cells was done using Manders’ coefficient (0.51 ± 0.05. n = 50 cells). b Calibration of endosomal pH in U87 cells (c) pH in
sorting endosomes is acidified in U87 cells transfected with miR-135a relative to scrambled control. Graph represents mean from three
biological replicates and at least 50 cells were used for pH quantification in each experiment. Error bars represent standard deviation (SD); *p <
0.05. Statistical analysis was done using student’s t-test
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pH in sorting endosomes is crucial for receptor sorting
and turnover. EGF receptor mediated signaling is a
powerful driver of glioblastoma. EGF binding to the re-
ceptors on the cell surface activates downstream kinase
cascades responsible for uncontrolled cell proliferation.
However, drugs designed to inhibit receptor kinase
phosphorylation have not been very successful due to re-
dundancy in signaling pathways and constitutively active
mutations. An alternative strategy to explore is decreas-
ing EGFR availability on the cell surface by manipulating
receptor turnover by altering the luminal pH of sorting
endosomes. We therefore, sought to determine the effect
of NHE9 downregulation via miR-135a transfection on
plasma membrane localization of EGFRs in U87 cells.
To this end, we first examined the effect of miR-135a on
total cellular EGFR expression. Western blot analysis in-
dicated cellular EGFR expression decreased by ~50% in
miR-135a transfected U87 cells relative to control
(Figs. 5A and B). This is consistent with a previous study
in prostate cancer cells, which showed miR-135a directly
a b c d
e
Fig. 5 miR-135a regulates NHE9 to limit number of EGF receptors on cell surface. a Immunoblot showing total and plasma membrane epidermal
growth factor receptor (EGFR) expression levels from U87 cells transfected with miR-135a or scrambled control. EGFR expression on plasma
membranes was determined by surface biotinylation (b and c) Graphs represents average band intensity from densitometric scans of immunoblots
from three biological replicates. Surface EGFR levels were normalized to total EGFR protein. MiR-135a not only downregulates EGFR expression but also
limits EGFR presence on the cell surface by inhibiting NHE9 expression. d Quantification of colocalization between LAMP1 and EGFR signals is shown
in the graph (n = 30 cells). Signal intensity and colocalization were measured with Image J software. Error bars represent standard deviation (SD); *p <
0.05. Statistical analysis was done using student’s t-test. e Colocalization of LAMP1 (green) and EGFR (red) images from immunofluorescence staining in
U87 cells transfected with miR-Scr and miR-135a. DAPI staining is shown in blue. Colocalization is indicated by yellow in the merge. Scale bar is 50 μm
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targets EFGR transcripts to downregulate their expres-
sion [38]. Furthermore, it was previously shown that ele-
vated expression of NHE9 limits EGFR degradation [7].
Therefore, the total decrease in EGFR protein we ob-
served could be a combination of transcript downregula-
tion by miR-135a and increased protein degradation.
Next, in EGF stimulated U87 cells we used surface bio-
tinylation to determine the plasma membrane density of
EGFRs. Compared to control, we observed ~70% de-
crease in EGFR surface expression in miR-135a trans-
fected U87 cells, after normalizing for total cellular
EGFR expression (Figs. 5A and C). In addition to down-
regulating EGFR expression in glioblastoma cells, our
data suggest that miR-135a affects EGFR turnover. To
confirm this, we used immunofluorescence microscopy
to examine localization of activated EGFRs with lyso-
somal marker LAMP1 in miR-135a transfected U87
cells. Consistent with miR-135a expression promoting
sorting of EGFRs for lysosomal degradation, we ob-
served a significant increase in colocalization of EGFR
with LAMP1 in miR-135a transfected cells (Manders’
coefficient, 0.85 ± 0.06 S.D., n = 30 cells) relative to
scrambled control transfected cells (Manders’ coeffi-
cient, 0.38 ± 0.10 S.D., n = 30 cells) (Figs. 5 D-E). To
demonstrate that differences in EGFR turnover are
linked to NHE9 levels, we ectopically expressed
NHE9-GFP in U87 cells transfected with miR-135a
following which we conducted experiments to quan-
tify EGFR levels on cell surface. Ectopic expression
increased NHE9 transcript levels by ~ 6.5 -fold
(Fig. 6A). NHE9-GFP transduction had no significant
effect on total EGFR expression (Fig. 6B ). Though
there was no significant change in EGFR transcript
levels in miR-135a transfected U87 cells overexpress-
ing NHE9 (Additional file 1: Figure S3), greater than
50% of EGFR plasma membrane expression was res-
cued in these U87 cells (Figs. 6C and D).
Taken together, our data clearly show that reduced
EGFR surface expression is causally related to the ob-
served proliferative and migratory phenotypes upon
miR-135a expression and NHE9 downregulation. Not-





Fig. 6 Ectopic NHE9 expression in miR-135a transfected cells rescues plasma membrane EGFR expression. a Relative increase in NHE9 transcript
upon ectopic expression of NHE9-GFP in miR-135a transfected U87 cells determined by quantitative real-time PCR analysis (b) No significant change in
EGFR transcript is observed in miR-135a transfected U87 cells upon ectopic expression of NHE9-GFP (c) Immunoblot showing rescue of epidermal
growth factor receptors (EGFRs) on cell surface upon ectopic NHE9-GFP expression in U87 cells transfected with miR-135a. EGFR expression on plasma
membranes was determined by surface biotinylation (d) Graph represents average band intensity from densitometric scans of immunoblots. Surface
EGFR levels were normalized to total EGFR protein. All graphs represent an average of at least three biological replicates. Error bars represent standard
deviation (SD), *p < 0.05 and **p < 0.01. Statistical analysis was done using student’s t-test
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miR-135a on cell growth and migration to a large ex-
tent, suggesting that the effect of miR-135a mediated
EGFR downregulation on these phenotypes could be
limited.
Discussion
NHE9 is implicated in multiple neurological diseases
including glioblastoma. However, regulation of its ex-
pression has not been reported till date. Here, we
show for the first time that miR-15a is a regulator of
NHE9 expression. In glioblastoma, overexpression of
NHE9 is a potent driver of tumor progression and is
associated with decrease in patient survival [7]. Un-
derstanding molecular mechanisms altering NHE9 ex-
pression may lead to more effective therapeutic and
diagnostic approaches. At a molecular level, mecha-
nisms affecting transcription, translation, rate of pro-
tein degradation or combinations of these are
potentially responsible for increase in NHE9 levels be-
yond a critical threshold. We propose attenuation of
miR-135a mediated downregulation of NHE9 as a
possible mechanism for NHE9 overexpression in glio-
blastoma. There is mounting evidence implicating
miRNA alterations in cancer initiation and progres-
sion [18–20]. MicroRNA-135a is enriched in glia and
is negatively correlated with the pathological grading
in gliomas [28]. NHE9 is one of the highly expressed
proteins in high-grade (grade IV) glioma [7]. Thus, it
is possible that loss of post-transcriptional regulation
via miR-135a could lead to NHE9 overexpression.
a b
c d
Fig. 7 Model for two-pronged regulation of EGFR signaling by miR-135a. Downregulation of EGFR and NHE9 expression in U87 cells by miR-135a
affects glioblastoma cell proliferation and migration. miR-135a reduces the total number of EGFRs by downregulating total cellular EGFR expression
and limits the (already) low EGFRs from reaching plasma membrane by downregulating NHE9 expression. a In U87 glioblastoma cells, miR-
135a expression is downregulated. EGFR transcript is translated in the cytosol and the receptors are transported to the cell surface. EGF
binding activates downstream signaling, which could turn oncogenic due to EGFR persistence on the plasma membrane leading to increased
cell proliferation and migration. b Upon expression of miR-135a gene, pre-miRNA 135a is transported out of the nucleus and is processed
in the cytoplasm resulting in mature miR-135a. Mature miR-135a binds to the 3’UTR of EGFR transcript resulting in degradation of the
mRNA. As a consequence of overall decrease in EGF receptors, oncogenic signaling is attenuated resulting in decreased cell proliferation
and migration. c Endocytosed receptors are sorted in the early/sorting endosome either for recycling or degradation in the lysosome. Luminal pH
in the sorting endosome regulates the route of their cargo. pH in these endosomes is governed by pump-leak mechanisms [7]. NHE9 expression
allows for protons to leak out in exchange for Na+ or K+ ions, thereby alkalinizing the lumen (pH = ~5.95). EGFR is trafficked in pH-defined endosomal
compartments within the cell. Increased leak due to NHE9 expression has been shown to recycle EGFR receptors back to the cell surface [7]. d In this
model, we show that downregulation of NHE9 expression via miR-135a acidifies the pH in the lumen of sorting endosomes (pH = ~5.63). Loss of NHE9
activity diverts the EGF receptors away from the plasma membrane towards the lysosomes, thus decreasing the number of EGFRs available for
oncogenic signaling
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Each gene may be regulated by more than one
miRNA [24]. Consistent with this, we show that
NHE9 is a putative target of both miR-124 and miR-
135a. Among miRNAs profiled in malignant gliomas,
miR-124 stands out to be one of the better-
characterized miRNAs. MiR-124 is the most abundant
miRNA in the brain and is expressed at significantly
lower levels in glioblastoma compared with non-
neoplastic brain tissue [39–41]. Ectopic expression of
miR-124 in U87 cell line resulted in significant inhib-
ition of migration and invasion [39]. However, role
for miR-124 in regulation of NHE9 expression awaits
further experimentation.
EGFR signaling pathways are promising targets for
therapeutic intervention in glioma [42]. However,
EGFR-targeting therapeutics have not been very ef-
fective. Redundancies in downstream signaling path-
ways, adaptive resistance of the receptor to inhibitors
have been attributed to the failure of these interven-
tions. Regulating NHE9 expression via miR-135a
based therapeutics could be explored to circumvent
problems associated with EGFR persistence on the
membrane. Our data supports the idea of a two-
pronged approach to regulation of EGFR signaling by
miR-135a (Fig. 7A-B). We show that ectopic expres-
sion of miR-135a in U87 glioma cells downregulates
EGFR expression. Furthermore, miR-135a expression
modulates endosomal pH by targeting NHE9 in U87
cells. Targeting endosomal pH limits trafficking of the
remaining few EGFR molecules to the plasma membrane
enhancing the efficiency of regulation (Fig. 7C-D). As a
consequence, up-regulation of miR-135a suppresses prolif-
eration and migration of glioblastoma cells. Evidence for a
similar multi-pronged approach to targeting proteins in a
single pathway by miR-135a has been reported in the
mitochondria-dependent apoptotic pathway where STAT6,
SMAD5 and BMPR2 were shown to be direct targets of
miR-135a [28, 38]. Silencing these three target genes was
shown to contribute to greater caspase-3/7 activity in
glioma.
Multiple miRNA-based therapeutics have reached
clinical development. In the context of miRNA ther-
apy, an important factor to consider is miR-135a’s
functional heterogeneity in different cell types. For
example, in melanoma cells mir-135a is upregulated
resulting in downregulation of the forkhead box O
1(FoxO1) protein, a transcription factor known for
its tumor suppressor role [43]. Here, miR-135a func-
tions more like an onco-miRNA turning on onco-
genic signaling pathways via FOXO1 repression.
Therefore, systemic administration of miR-135a in
the body may not be tolerated. However, there are
no known reports of intolerance in other brain cell
types to miR-135a.
Conclusions
In conclusion, we identify for the first time a regulator
for NHE9, implicated in multiple neurological diseases.
We propose downregulation of miR-135a that is nor-
mally enriched in glial cells as a potential mechanism
leading to increase in NHE9 expression beyond a critical
threshold, which drives oncogenic signaling in a subset
of glioblastomas. Taken together, our findings indicate
miR-135a is compelling target for therapeutic develop-
ment in NHE9 overexpressing glioblastoma.
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